|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/20 Akers Biosciences, Inc. 10-K 12/31/19 80:11M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 995K
2: EX-3.10 Articles of Incorporation/Organization or Bylaws HTML 28K
3: EX-4.12 Instrument Defining the Rights of Security Holders HTML 52K
4: EX-21.1 Subsidiaries List HTML 23K
5: EX-23.1 Consent of Experts or Counsel HTML 23K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
71: R1 Document and Entity Information HTML 59K
35: R2 Consolidated Balance Sheets HTML 107K
25: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
47: R4 Consolidated Statements of Operations and HTML 96K
Comprehensive Loss
70: R5 Consolidated Statement of Changes in Shareholders' HTML 87K
Equity
34: R6 Consolidated Statement of Changes in Shareholders' HTML 29K
Equity (Parenthetical)
23: R7 Consolidated Statements of Cash Flows HTML 132K
46: R8 Organization and Description of Business HTML 29K
72: R9 Significant Accounting Policies HTML 105K
27: R10 Recent Developments, Liquidity and Management's HTML 30K
Plans
37: R11 Inventories HTML 32K
79: R12 Property, Plant and Equipment HTML 32K
54: R13 Intangible Assets HTML 40K
28: R14 Trade and Other Payables HTML 29K
38: R15 Share-based Compensation HTML 78K
80: R16 Equity HTML 43K
55: R17 Income Taxes HTML 43K
29: R18 Commitments and Contingencies HTML 67K
36: R19 Related Parties HTML 30K
64: R20 Revenue Information HTML 34K
56: R21 Employee Benefit Plan HTML 26K
15: R22 Subsequent Events HTML 41K
41: R23 Significant Accounting Policies (Policies) HTML 176K
65: R24 Significant Accounting Policies (Tables) HTML 43K
57: R25 Inventories (Tables) HTML 30K
16: R26 Property, Plant and Equipment (Tables) HTML 32K
42: R27 Intangible Assets (Tables) HTML 41K
63: R28 Trade and Other Payables (Tables) HTML 28K
58: R29 Share-based Compensation (Tables) HTML 84K
53: R30 Income Taxes (Tables) HTML 44K
77: R31 Commitments and Contingencies (Tables) HTML 28K
40: R32 Revenue Information (Tables) HTML 35K
31: R33 Significant Accounting Policies (Details HTML 115K
Narrative)
52: R34 Significant Accounting Policies - Schedule of HTML 29K
Marketable Securities (Details)
76: R35 Significant Accounting Policies - Schedule of HTML 41K
Estimated Useful Life of Property Plant and
Equipment (Details)
39: R36 Significant Accounting Policies - Schedule of HTML 28K
Estimated Useful Life of Other Intangible Assets
(Details)
30: R37 Significant Accounting Policies - Schedule of HTML 35K
Anti-dilutive Securities Excluded from Computation
of Earnings Per Share (Details)
51: R38 Recent Developments, Liquidity and Management's HTML 33K
Plans (Details Narrative)
78: R39 Inventories (Details Narrative) HTML 33K
62: R40 Inventories - Schedule of Inventories (Details) HTML 37K
68: R41 Property, Plant and Equipment (Details Narrative) HTML 26K
44: R42 Property, Plant and Equipment - Schedule of HTML 49K
Property, Plant and Equipment (Details)
18: R43 Intangible Assets (Details Narrative) HTML 29K
61: R44 Intangible Assets - Schedule of Finite-Lived HTML 36K
Intangible Assets (Details)
67: R45 Intangible Assets - Schedule of Estimated HTML 40K
Aggregate Amortization Expense of Fiscal Years
(Details)
43: R46 Trade and Other Payables - Schedule of Trade and HTML 34K
Other Payables (Details)
17: R47 Share-based Compensation (Details Narrative) HTML 75K
60: R48 Share-based Compensation - Summary of Stock HTML 88K
Options Activity (Details)
69: R49 Share-based Compensation - Summary of Restricted HTML 52K
Stock Units Activity (Details)
74: R50 Share-based Compensation - Summary of Warrant HTML 85K
Activity (Details)
48: R51 Equity (Details Narrative) HTML 96K
21: R52 Income Taxes (Details Narrative) HTML 44K
32: R53 Income Taxes - Schedule of Income Tax (Benefit)/ HTML 37K
Provision (Details)
75: R54 Income Taxes - Schedule of Reconciliation of HTML 44K
Income Taxes using Statutory U.S. Income Tax Rate
and Benefit from Income Taxes (Details)
49: R55 Income Taxes - Schedule of Deferred Tax Assets and HTML 38K
Related Valuation Allowances (Details)
22: R56 Commitments and Contingencies (Details Narrative) HTML 111K
33: R57 Commitments and Contingencies - Schedule of Lease HTML 29K
Commitments (Details)
73: R58 Related Parties (Details Narrative) HTML 42K
50: R59 Revenue Information (Details Narrative) HTML 27K
19: R60 Revenue Information - Schedule of Revenue by HTML 31K
Product Lines (Details)
45: R61 Revenue Information - Schedule of Revenue by HTML 28K
Geographic Area Determined Based On Location of
Customers (Details)
66: R62 Employee Benefit Plan (Details Narrative) HTML 31K
59: R63 Subsequent Event (Details Narrative) HTML 62K
20: XML IDEA XML File -- Filing Summary XML 140K
26: EXCEL IDEA Workbook of Financial Reports XLSX 96K
9: EX-101.INS XBRL Instance -- aker-20191231 XML 1.40M
11: EX-101.CAL XBRL Calculations -- aker-20191231_cal XML 192K
12: EX-101.DEF XBRL Definitions -- aker-20191231_def XML 658K
13: EX-101.LAB XBRL Labels -- aker-20191231_lab XML 1.37M
14: EX-101.PRE XBRL Presentations -- aker-20191231_pre XML 884K
10: EX-101.SCH XBRL Schema -- aker-20191231 XSD 248K
24: ZIP XBRL Zipped Folder -- 0001493152-20-004650-xbrl Zip 161K
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Howard Yeaton, certify that:
| 1. | I have reviewed this Form 10-K of Akers Biosciences, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; | |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: March 24, 2020 | By: | /s/ Howard Yeaton |
| Howard Yeaton | ||
| Interim Chief Financial Officer (Principal Financial and Accounting Officer) |
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 3/25/20 | |||
| Filed on: | 3/24/20 | 8-K, CORRESP | ||
| For Period end: | 12/31/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/19/21 MyMD Pharmaceuticals, Inc. S-4/A 121:17M M2 Compliance LLC/FA 3/01/21 MyMD Pharmaceuticals, Inc. 10-K 12/31/20 69:7.8M M2 Compliance LLC/FA 1/15/21 MyMD Pharmaceuticals, Inc. S-4 6:9.5M M2 Compliance LLC/FA 11/16/20 MyMD Pharmaceuticals, Inc. 10-Q 9/30/20 57:6.6M M2 Compliance LLC/FA 10/21/20 MyMD Pharmaceuticals, Inc. 10-K/A 12/31/19 6:1.1M M2 Compliance LLC/FA 9/08/20 MyMD Pharmaceuticals, Inc. 424B3 1:153K M2 Compliance LLC/FA 8/18/20 MyMD Pharmaceuticals, Inc. S-3 3:265K M2 Compliance LLC/FA 8/14/20 MyMD Pharmaceuticals, Inc. 10-Q 6/30/20 59:6M M2 Compliance LLC/FA |